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1
It is well recognized that the agouti/melanocortin sys-
tem is an important regulator of body weight homeosta-
sis. Given that agouti is expressed in human adipose
tissue and that the ectopic expression of agouti in
adipose tissue results in moderately obese mice, the
link between agouti expression in human adipose tissue
and obesity/type 2 diabetes was investigated. Although
there was no apparent relationship between agouti
mRNA levels and BMI, agouti mRNA levels were signif-
icantly elevated in subjects with type 2 diabetes. The
regulation of agouti in cultured human adipocytes re-
vealed that insulin did not regulate agouti mRNA,
whereas dexamethasone treatment potently increased
the levels of agouti mRNA. Experiments with cultured
human preadipocytes and with cells obtained from
transgenic mice that overexpress agouti demonstrated
that melanocortin receptor (MCR) signaling in adipose
tissue can regulate both preadipocyte proliferation and
differentiation. Taken together, these results reveal
that agouti can regulate adipogenesis at several levels
and suggest that there are functional consequences of
elevated agouti levels in human adipose tissue. The
influence of MCR signaling on adipogenesis combined
with the well-established role of MCR signaling in the
hypothalamus suggest that adipogenesis is coordinately
regulated with food intake and energy expenditure.
Diabetes 52:2914–2922, 2003
O
ver the past decade, it has become apparent
that the agouti/melanocortin system is a critical
component of several biological pathways, in-
cluding body weight homeostasis. Many ge-
netic and pharmacological studies have shown that agouti
and agouti-related protein (AGRP) compete with pro-
opiomelanocortin (POMC)-derived peptides for binding
sites on melanocortin receptors (MCRs) to regulate food
intake and energy expenditure. Altered expression levels
of agouti (1,2), AGRP (3,4), MC3-R (5) and MC4-R (6), and
POMC (7) have been shown to disrupt the control of body
weight in mice. However, to date, there have been no
published observations implicating agouti, per se, in hu-
man obesity or type 2 diabetes.
The mouse and human agouti proteins are structurally
similar, but the expression pattern of the mouse and
human agouti genes is very different. The transcription of
the wild-type mouse agouti is temporally regulated, being
expressed solely in the skin during part of the hair growth
cycle (1). Human agouti is expressed in diverse tissues:
adipose tissue, testis, heart, liver, kidney, ovary, and skin
(8,9). The divergence in expression patterns between mice
and humans strongly suggests that agouti may have func-
tions other than pigmentation in humans. The presence of
agouti, and MCRs, in human adipose tissue raises ques-
tions as to their normal function in adipose tissue and
whether dysregulation of agouti in adipose tissue might be
associated with an obese, insulin-resistant, or diabetic
phenotype.
In the original human agouti cloning study by Kwon et
al. (8), an RT-PCR analysis of RNA obtained from subcu-
taneous fat from three normal females revealed agouti
expression in two of the three fat samples and suggested
that agouti might be differentially regulated in humans.
More recently, agouti mRNA was found to be negatively
correlated with BMI in men but not in women (10). In our
recent studies, we engineered transgenic mice to overex-
press agouti in adipose tissue in order to study the
potential biological role of agouti/melanocortin signaling
in human adipose tissue (11). The aP2-agouti transgenic
mice become significantly heavier than nontransgenic
littermates by 8–10 weeks of age and have almost a
twofold increase in fat mass compared with nontransgenic
mice (12). Moreover, there were no detectable changes in
food intake in the aP2-agouti mice, suggesting changes in
energy utilization and/or nutrient partitioning (13).
In the present study, expression levels of human agouti
and MCRs were studied in human mesenchymal stem cells
as they were differentiated into lipid-storing adipocytes.
Having established the presence of both agouti and MCRs
in human adipose tissue, agouti expression levels were
measured in patients with a wide range in BMI and in
patients with type 2 diabetes. Additionally, experiments
with transgenic mice that express agouti in adipose tissue
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and isolated preadipocytes were used to determine
whether there was a possible functional role of the agouti/
melanocortin system in adipose tissue. Several interesting
findings have emerged from these experiments. The data
demonstrate that human agouti expression is upregulated
by glucocorticoids and that agouti and the cortisol-produc-
ing enzyme 11 hydroxysteroid dehydrogenase type 1
(11-HSD-1) are upregulated in patients with type 2 dia-
betes. Third, we find that the agouti/melanocortin system
is a potent and direct regulator of adipogenesis.
RESEARCH DESIGN AND METHODS
Human mesenchymal cell differentiation. Cells (BioWhittaker) were
plated at a density of 2–5  103/cm2 and grown at 37°C in an atmosphere of
95% air and 5% CO2 as previously described (14). Cells were grown to 100%
confluence in the growth medium supplemented with 5% fetal bovine serum
(FBS). Five-day postconfluent cells were incubated in adipogenesis induction
medium (AIM-M199; 1 mmol/l dexamethasone, 0.2 mmol/l indomethacin, 170
nmol/l insulin, 0.5 mmol/l isobutyl-methylxanthine [IBMX], 10% FBS, 0.05
units/ml penicillin, and 0.05 g/ml streptomycin) for 3 days. Next, the cells
were incubated for 1 day in adipogenesis maintenance medium (AMM-M199;
170 nmol/l insulin, 10% FBS, 0.05 units/ml penicillin, and 0.05 g/ml strepto-
mycin) and then switched to AIM for 3 days. After a third exposure to AIM,
cells were maintained in AMM for up to 21 days after the initiation of
differentiation.
Isolation and differentiation of mouse preadipocytes. Epididymal and
inguinal fat pads, collected from 19- to 21-day-old FVB, -actin promoter-
agouti (BAP-agouti), and aP2-agouti mice, were minced and digested with
collagenase class I (2 mg/ml; Worthington Biochemical) in a shaking bath for
1 h at 37°C. Dissociated cells were filtered through a 100 mol/l cell strainer
(Becton Dickinson Labware) and separated by centrifugation at 360g for 5
min. Pelleted preadipocyte cells were resuspended for 1 min. in erythrocyte
lysis buffer (Sigma) to remove erythrocyte contamination and centrifuged at
360g for 5 min. Cells were plated in 35-mm Petri dishes (p  0) in DMEM/F12
medium (Invitrogen Life Technologies) supplemented with 15% of FBS
(Invitrogen Life Technologies) or in complete medium. Subconfluent primary
cultures were trypsynized and replated (p  1) at 2  104/cm2 in a 24-well
culture plate and kept in complete medium. At confluency, cells received
differentiation medium (DMEM/F12 with 5% FBS supplemented with 1.7
mol/l insulin, 1 mol/l dexamethasone, and 0.5 mmol/l IBMX for 5 days. In
the experiment in which RNA was collected from the adipocytes, the medium
was replaced with DMEM/F12 with 5% FBS for 2 additional days in the
presence of 2 mol/l rosiglitazone and 10 nmol/l insulin. To measure lipid
content in the adipocytes, cells were fixed in 10% solution of formaldehyde in
aqueous phosphate buffer for 1 h, washed with 60% isopropanol, and stained
with Oil Red-O solution (in 60% isopropanol) for 10 min. The cells were then
repeatedly washed with water, photographed, and destained in 100% isopro-
panol for 15 min. The optical density of the isopropanol solution was
measured at 500 nm.
Human biopsies. All human studies were performed after institutional
review board approval and written informed consent were obtained. After
local anesthesia, adipose tissue was collected by needle biopsy of the
superficial subcutaneous adipose tissue lateral to the umbilicus.
Mice. Transgenic mice were maintained on the FVB/N background at the
Pennington Biomedical Research Center as previously described (11). All
mice were fed a diet containing 11% fat by weight (Mouse Diet 5015; Purina
Mills). Food and water were provided ad libitum. All data are from mice that
are hemizygous for the transgene or their nontransgenic littermates.
RNA isolation and RT-PCR analysis. Total RNA was isolated by the Trizol
method (Life Technologies) and applied to Rneasy columns (Qiagen). The
concentration of RNA was determined using spectrophotometry, and the
quality was verified by visualizing on a gel. For nonquanitative RT-PCR, 1 g
total RNA was used for the cDNA synthesis and 1:40 of that reaction was used
as a PCR template.
The following primer sets were used. Human (forward, reverse primer):
agouti (TGTCTCTATTGTGGCGCTGAA, GGAAGAAGCGGCACTG); MC1-R
(GCAGCAGCTGGACAATGTCA, ATGAAGAGCGTGCTGAAGACG); MC2-R (A
TCACCTTCACGTCGCTGTT, CGTTATTCCCATGGATTCTA); MC3-R (CCAAA
AGAAGTATCTGGAG, AGTTCATGCCGTTGCAGCC); MC4-R (GCTACGAGCA
ACTTTTTCTC, GTACTGGAGAGCATAGAAG); MC5-R (ACCTGCACTCCCCC
ATGTAC, CAGGCACTGGACATGCTCAC); peroxisome proliferator–activated
receptor (PPAR) (TGCCAAAAGCATTCCTGGTT, CGCTGTCATCTAATTCCA
GTGC); adipsin (CAGGGTCACCCAAGCAACA, CAGGGTCACCCAAGCAA
CA); cyclophilin (GGAGATGGCACAGGAGGAAA, CGTAGTGCTTCAGTTTGA
AGTTCTCA). Mouse (forward, reverse primer): MC1-R (CACTCAGGAGCCC
CAGAAGA, CACCAGACTCACCAGCCCTAG); MC2-R (GCGCCGCACCATC
ATC, GGGAGCGGGCAAGTAAGAAC); MC3-R (CTCTGGGCATCGTCAGTC
TGA, GGATAAACTGGTCCTCCAAGGTC); MC4-R (GCGGGTCGGGATCA
TCA, GGTACCCTGGCGGATGGT); MC5-R (AGGTGTTCCTGACCCTGGGT,
CAGGCATTGGACATGCTCAC); PPAR (AGAGTCTGCTGATCTGCGAGC, CG
GATCGAAACTGGCACC); aP2 (GTGATGCCTTTGTGGGAACC, CGCCCAGTT
TGAAGGAAATCT); cyclophilin (TCCATCGTGTCATCAAGGACTT, CTCATCT
GGGAAGCGCTCA).
The taqman probe primer system (Applied Biosystems) was used for quanti-
tative RT-PCR. Primer/probe sets are as follows. Agouti: forward CAACTCC
T-CTGTGAACCTACTGGAT, probe 6-FAM-CCCTTCTGTCTCTATTGTGgcGCT
GAAC-BHQ (lower case letters denote intro/exon boundry), reverse TGCCG
ATCTGTTTGGATTTCT; 11-HSD-1: forward GGCTTATCATCTGGCGAAG
ATG, probe 6-FAM-GGATACCACCTTCTGTAGAGTTTCTTTT-BHQ, reverse
ACCTCGCTGTCACCACCACATGGG. RT-PCR was carried out in one tube
using the ABI PRISM 7700 SDS instrument (Applied Biosystems) using 50 ng
total RNA as the template. The master mix included 300 nmol/l primers, 100
nmol/l probe, reverse transcriptase MuLV, RNase inhibitor, and AmpliTaq
GOLD (Applied Biosystems). The Ct value for every sample was measured in
duplicate, and mRNA levels were normalized to cyclophilin mRNA levels
(forward GGAGATGGCACAGGAGGAAA, probe 6-FAM-CATCTACGGTGAGC
GCTTCCCCG-BHQ, reverse CGTAGTGCTTCAGTTTGAAGTTCTCA). The
agouti and MCR PCR products were cloned into a T/A cloning vector and
sequenced.
Cell proliferation assay. Human preadipocytes were purchased from Zen
Bio. The donors were five healthy women between 20 and 60 years of age. The
average BMI was 26.6 kg/m2, and none were morbidly obese. Preadipocytes
were isolated by centrifugal force after collagenase treatment. We received
undifferentiated preadipocytes at passage 2 and plated equal numbers of cells
in a 96-well plate. The cells were cultured in DMEM/F-10 (1:1 [vol/vol]) with
10% FBS until 50% confluence. The human cells were then treated with the
various combinations of  melanocyte-stimulating hormone (MSH) and
murine agouti (93aa-132aa; Phoenix Pharmaceuticals) overnight. The next
morning, fresh media containing BrdU was added. Three hours later, BrdU
uptake was measured by enzyme-linked immunosorbent assay (ELISA) (Am-
ersham Pharmacia). For mouse preadipocyte proliferation assays, preadipo-
cytes were isolated from 19- to 21-day-old mice by collagenase digestion and
centrifugation. The preadipocytes were grown to confluence, trypsinized, and
split equally into 96-well plates. The mouse cells were then treated with the
various combinations of MSH and agouti overnight. The next morning, fresh
media containing BrdU was added. Three hours later, BrdU uptake was
measured by ELISA (Amersham Pharmacia).
Statistical analyses. Unpaired t tests were used to compare diabetic and
nondiabetic individuals (JMP version 4.0; SAS Institute, Cary, NC). Agouti and
11-HSD-1 mRNA expression were compared across sex and diabetes status
using a two-way ANOVA. Correlation between agouti and BMI was performed
using Pearson correlation. Statistical significance was set a priori at 0.05.
RESULTS
The MCR status in FVB/N mouse adipose tissue and each
of the cell lines used in these experiments were tested
because different mouse strains may express different
MCR, receptor status may be affected by culture condi-
tions, and cell lines can change over time. To our knowl-
edge, there is only one publication on the expression of
MCRs in human adipose tissue, and this study indicates
that all MCRs are expressed in human subcutaneous fat
(15). In the present study, RNA was isolated from human
mesenchymal stem cells and 3T3-L1 cells as they differen-
tiated into adipocytes, as described in RESEARCH DESIGN AND
METHODS. RNA was also obtained from intact mouse ingui-
nal and human subcutaneous fat and from mouse adipose
tissue after it was fractionated into stromal vascular and
adipocyte fractions. The presence of all known MCR was
then examined by RT-PCR. As shown in Fig. 1A, both
MC1-R and MC2-R were detected in the human mesenchy-
mal stem cells before and after differentiation and in
human adipose tissue. MC1-R was found predominately in
the preadipocyte fraction and MC2-R predominately in the
adipocyte fraction. The other MCRs were not detected in
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human cells or fat. A critical problem with RT-PCR detec-
tion of MCR mRNA is that the MCR genes are intronless.
Therefore only a small amount of genomic DNA contami-
nation in the RNA preparation will give a false-positive. It
is unclear if the human RNA purchased for the previous
study (15) was DNAse treated for the RT-PCRs. Hence, it
is possible that the commercial RNA may have been
contaminated with genomic DNA.
RT-PCR analysis detected both MC2-R and MC5-R in
murine 3T3-L1 cells (Fig. 1B) as they differentiated into
adipocytes, an observation which is consistent with a
previous study on the MCR subtype expression in 3T3-L1
adipocytes (16). None of the other MCR subtypes were
detectable in 3T3-L1 cells. MC2-R and MC5-R were detect-
able in FVB/N mouse adipose tissue, and they were found
primarily in the adipocyte fraction. MC1-R, MC2-R, and
MC5-R were found in mouse preadipocyte culture (Fig.
1C).
To examine the agouti expression pattern during human
adipocyte differentiation, human mesenchymal stem cells
were cultured to 95% confluence and induced to differen-
tiate as described in RESEARCH DESIGN AND METHODS. We
observed that the expression of agouti mRNA increased
through each cycle of exposure to the differentiation
media and declined when the cells were returned to basal
media (Fig. 2A and B). The decline in agouti expression
that occurred when cells were returned to the basal media
suggested that individual components of the differentia-
tion media were capable of regulating agouti expression.
We observed that the addition of dexamethasone to either
confluent mesenchymal stem cells or differentiated adipo-
cytes increased agouti expression to the same level ob-
served with the complete differentiation cocktail (Fig. 2C).
These in vitro results indicate that glucocorticoids upregu-
late agouti expression in human adipocytes.
Since transgenic mice that express agouti in adipose
tissue become obese (12), agouti mRNA was quantitated in
the subcutaneous fat from humans with a broad range of
BMIs. There was no correlation between agouti expres-
sion levels and BMI in either men or women (Fig. 3A).
However, agouti mRNA was significantly greater in
women than in men (Fig. 3B). Agouti mRNA was also
measured in individuals with type 2 diabetes with body fat
similar to moderately obese people (Table 1 and Fig. 3A).
There were significantly higher levels of agouti expression
in diabetic subjects than in nondiabetic individuals (Table
1 and Fig. 3B). The data in Fig. 3A demonstrate that type
2 diabetic subjects have higher agouti levels than nondia-
betic subjects across a range of BMIs. Again there was a
FIG. 1. RT-PCR analysis of MCRs in mouse and human adipose tissue and adipocytes. A: RNA was isolated from human mesenchymal stem cells
as they were differentiated into adipocytes, as described in RESEARCH DESIGN AND METHODS (lanes 2-5), from preadipocytes that were isolated from
human subcutaneous fat and grown to confluence (lane 6) and after they were differentiated into adipocytes (lane 7) and from whole human
subcutaneous fat (lane 8). B: RNA was isolated from 3T3-L1 mouse adipocytes as they were differentiated into adipocytes, from whole mouse fat
pads, and from mouse fat that had been separated into the stromal vascular and adipocyte fractions by collagenase digestion and centrifugation.
C: RNA was isolated from mouse preadipocytes isolated from combined white fat depots and grown to confluence. For all samples, first-strand
cDNA was synthesized from 2 g total RNA and 1/40th of the reaction was used as template for 35 cycles of PCR.
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sex effect, with diabetic women having the highest overall
agouti expression levels (Fig. 3B).
Cell culture experiments with either confluent preadi-
pocytes or differentiated adipocytes demonstrated that
glucocorticoids potently increase agouti expression. While
elevated glucocorticoid levels may play a significant role in
the development of obesity and type 2 diabetes (17), there
are no definitive reports linking elevated circulating glu-
cocorticoid levels to the obese/diabetic state. Additionally,
we found no relationship between cortisol secretion (as
measured by salivary cortisol) and agouti mRNA (data not
shown). However, the enzyme 11-HSD-1 can regulate
intracellular glucocorticoid concentrations by regenerat-
ing active glucocorticoid (cortisol in humans, corticoste-
rone in mice) from inactive cortisone and 11-
dehydrocorticosterone. We observed that 11-HSD-1
mRNA levels were significantly higher in the same cohort
of diabetic subjects that had elevated agouti expression
levels (Fig. 3C), demonstrating another correlation be-
tween glucocorticoids and agouti.
Having observed the elevated agouti levels in diabetic
humans, transgenic mice and cell culture experiments
were used to determine whether there were functional
consequences of agouti expression in adipose tissue. Mi-
croarray data from 3-week-old aP2-agouti transgenic mice
suggested a relationship between agouti expression and
preadipocyte hyperplasia (data not shown). Therefore, we
measured the DNA content from the epididymal fat pads
of aP2-agouti transgenic mice to determine cell density.
Both total DNA and DNA per milligram fat were signifi-
cantly higher in the transgenic mice at 4 weeks of age,
indicating that more preadipocytes were present in the fat
pads of aP2-agouti mice (Fig. 4A). The increased amount
of DNA in the fat of aP2-agouti mice led us to examine the
effects of agouti and MSH on preadipocyte proliferation
in vitro. We observed that MSH inhibited proliferation in
both mouse and human preadipocytes (Fig. 4B and C). Our
data also indicate that agouti has a slight stimulatory effect
on proliferation, but it is clear that agouti blocked the
inhibitory effects of MSH. Interestingly, AGRP was not
able to block the inhibitory effects of MSH on prolifera-
tion (data not shown). Forskolin was also a potent inhib-
itor of proliferation, but agouti was not able to block the
inhibitory effects of forskolin (data not shown). These
data, taken together with the increased DNA content at 4
weeks of age in the aP2-agouti mice, suggest that MSH
and agouti regulate adipocyte proliferation in a reciprocal
fashion.
Several studies have shown that PPAR is an essential
transcription factor for differentiation and maturation of
adipocytes (18–24). Additionally, ectopic expression of
PPAR in nonprecursor fibroblast cells promotes lipid
accumulation and confers the characteristics of mature
adipocytes (25). Recent studies have also suggested that
the STAT (signal transducers and activators of transcrip-
tion) family of transcription factors may also be important
in fat cells (26–29). We have previously shown that both
agouti treatment of 3T3-L1 adipocytes and agouti expres-
FIG. 2. Quantitation of agouti mRNA in human fat and adipocytes. A: RT-PCR analysis of agouti during the differentiation of human mesenchymal
stem cells into adipocytes. PPAR and adipsin were measured as markers of differentiation. B: Quanitative RT-PCR of agouti during human
mesenchymal stem cell differentiation into adipocytes. Gray blocks show the times when cells were fed with adipocyte differentiation media (FBS
 insulin  dexamethasone [Dex]  IBMX). At all other times, the cells were fed with FBS and insulin. C: Regulation of agouti by dexamethasone
and IBMX in differentiated human adipocytes. Indom, indomethacin.
S.R. SMITH AND ASSOCIATES
DIABETES, VOL. 52, DECEMBER 2003 2917
sion in mouse adipose tissue increases STAT1, STAT3, and
PPAR protein levels (13). Since PPAR is a key regulator
of adipocyte differentiation and agouti induces PPAR, we
initiated experiments to address the ability of agouti to
influence adipocyte differentiation. The levels of differen-
tiation were measured by lipid accumulation in nontrans-
genic and BAP-agouti transgenic mice (30). Cells from the
BAP-agouti mice were included in this study because the
B-actin promoter will drive agouti expression in the prea-
dipocytes. However, preadipocytes isolated from the aP2-
agouti mice should not express agouti because the aP2
promoter is not active until late in adipocyte differentia-
tion. Preadipocytes were isolated from 19- to 21-day-old
mice by collagenase digestion and centrifugation. The
preadipocytes were plated and grown to confluence and
induced to differentiate as described in RESEARCH DESIGN AND
METHODS. After 5 days of differentiation, the cells were
stained with Oil Red-O to measure lipid accumulation.
Only 20% of the cells from wild-type mice had significant
lipid accumulation (Fig. 5A). However, both the addition
of 10 nmol/l COOH-terminal agouti peptide to wild-type
preadipocytes (Fig. 5B) and the ectopic expression of
agouti (Fig. 5C) caused a significant increase Oil Red-O
staining. After photography, the Oil Red-O was extracted
from the adipocytes and quantified (Fig. 5D), further
demonstrating that agouti increases adipocyte differentia-
tion. In a separate set of experiments, RNA was extracted
from the confluent preadipocytes and daily after addition
of the differentiation cocktail. PPAR mRNA is already at
high levels in the confluent preadipocytes isolated for the
BAP-agouti transgenic mice. Additionally, aP2 mRNA ap-
pears earlier, and the band is more intense in the preadi-
pocytes isolated from the transgenic mice. The data
presented in Fig. 5 demonstrate that agouti treatment of
preadipocytes from nontransgenic mice increases adipo-
genesis in vitro and that endogenous expression of agouti
increases adipogenesis in vitro and in vivo.
DISCUSSION
The hypothalamic melanocortin system is an important
regulator of body weight and appetite. The aim of these
studies was to understand the role of the melanocortin
system in adipose tissue. These studies reveal for the first
time that expression of agouti mRNA is increased in
diabetes, but not obesity, and that glucocorticoids upregu-
late agouti mRNA in vitro. They also reveal that there is
increased expression of the cortisol-activating enzyme
11-HSD-1 in diabetes. We also provide compelling data
FIG. 3. Expression of agouti and 11-HSD-1 mRNA in human subcuta-
neous adipose tissue. Agouti and 11-HSD-1 mRNAs were measured as
described in RESEARCH DESIGN AND METHODS and normalized to cyclophilin
mRNA. A: There was no relationship between BMI and agouti mRNA,
but agouti (B) and 11-HSD-1 (C) mRNA are increased in diabetes.
T2DM, type 2 diabetes.
TABLE 1






Sex (F/M) 8/17 7/12 NA
Race (black/white) 7/17 5/14 NA
BMI (kg/m2) 29.12  4.40 32.55  5.23 0.01
Body fat (%) 30.10  8.70 32.76  8.99 NS
Waist (cm) 94.96  12.30 108.05  12.26 	0.001
Insulin (U/ml) 11.70  7.12 17.14  9.42 0.01
Glucose (mg/dl) 95.40  10.40 182.32  48.55 	0.001
Triglyceride
(mg/dl) 139.68  63.34 230.16  206.23 0.01
HbA1c (diabetic
subjects only) N/A 7.71  1.85 NA
Agouti/cyclophilin
mRNA 1.56  1.42 3.44  1.90 	0.001
11-HSD-1/
cyclophilin
mRNA 0.61  0.11 1.15  0.10 	0.001
Data are means  SD.
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on the functional consequences of local agouti production;
MSH inhibits proliferation of human and murine preadi-
pocytes, and agouti blocks this effect. Furthermore, agouti
enhances differentiation of murine and human preadipo-
cytes in vitro. Combined with previous data demonstrating
that agouti upregulates PPAR protein levels, this suggests
that agouti is a paracrine factor in adipose tissue that can
regulate both proliferation and differentiation of preadipo-
cytes.
In addition to the effects of agouti on adipogenesis,
there is considerable precedence for the regulation of
mature adipocyte metabolism by agouti and POMC-de-
rived peptides. The mRNA levels for fatty acid synthase
and stearoyl-CoA desaturase, two key enzymes in de novo
fatty acid synthesis and desaturation, respectively, were
dramatically increased in obese (Avy) mice relative to lean
(a/a) controls (31). Additionally, treatment of fully differ-
entiated 3T3-L1 adipocytes with recombinant agouti pro-
tein increased fatty acid synthase and stearoyl-CoA
desaturase mRNA levels (31). A potential mechanism for
the increased fatty acid synthase and stearoyl-CoA desatu-
rase levels is that they are transcriptional targets of
PPAR. In opposition to the adipogenic effects of agouti,
ACTH, MSH, and -LPH are potent lipolytic hormones,
but considerable interspecies variability exists in the lipo-
lytic response of adipocytes to melanocortins (32). The
negative effects of melanocortins on adipogenesis (inhibi-
tion preadipocyte proliferation and increased lipolysis),
combined with the positive effects of agouti on adipogen-
esis (increased PPAR and differentiation), strongly sug-
gest a coordinate control of the adipogenesis.
Agouti appears to antagonize MSH and ACTH stimula-
FIG. 4. Effects of agouti preadipocyte proliferation. A: As an estimate of cell density, DNA content was measured in aP2-agouti and nontransgenic
mice at 4, 6, 8, and 10 weeks of age (n  5–7 mice per data point). Data are presented as mean  SE. B and C: Preadipocytes from mice and humans
were isolated by centrifugal force after collagenase treatment. They were grown to confluence, trypsinized, and split equally into 96-well plates.
The cells were then treated with the various combinations of MSH and agouti overnight. The next morning, fresh media containing BrdU was
added. Three hours later, BrdU uptake was measured by ELISA. Data are means  SE from three separate experiments. *P < 0.05 vs. control
values.
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tion of cAMP at all five of the MCRs (33,34). MSH
stimulates cAMP levels at all the MCRs except MC2-R, and
ACTH stimulates cAMP levels at all the MCRs (33). Previ-
ous studies demonstrated that mouse adipocytes express
high-affinity binding sites for melanocortin peptides (35)
and that MC1-R, MC2-R, and MC5-R are expressed in
adipocytes and adipose tissue (16,36). In these studies,
high expression levels of MC1-R and low levels of MC2-R
were observed in the human preadipocytes (Fig. 1), and
based on the inactivity of MSH at MC2-R, it is logical to
suggest that MC1-R is responsible for the antiproliferative
effects of MSH in preadipocytes.
It should be noted that the inhibitory effects of MSH
cellular proliferation are not restricted to preadipocytes.
One of the hallmark phenotypes of the yellow obese
syndrome is neoplasia and an increased incidence of
tumors (reviewed by Wolff et al. [37] and Yen et al. [38]).
Additionally, treatment of melanocytes with MSH pro-
motes terminal differentiation, resulting in an inhibition of
proliferation, and agouti reverses MSH effects and inhib-
its pigmentation and promotes proliferation (39–41).
We have previously shown that agouti increases PPAR
expression in fully differentiated 3T3-L1 adipocytes and in
mice that ectopically express agouti in adipose tissue
(12,13). The present study demonstrates that agouti stim-
ulates adipocyte differentiation. Once again, the mecha-
nism appears to be mediated through PPAR, since
PPAR mRNA levels are as high in the confluent undiffer-
entiated preadipocytes from agouti-expressing mice, as
compared with the fully differentiated adipocytes.
Perhaps the most clinically relevant findings are the
upregulation of human agouti by glucocorticoids and the
elevated levels of agouti and 11-HSD-1 mRNA in subcu-
taneous fat from patients with type 2 diabetes. Taken
together, these data suggest a model where by the hyper-
glycemia of diabetes activates 11-HSD-1 transcription
and increased local production of cortisol, which then
increases agouti mRNA. An alternate explanation is that a
common factor on induces both agouti and 11-HSD-1
transcription. Given that dexamethasone potently upregu-
lates agouti in vitro, we hypothesize that the paracrine
model depicted in Fig. 6 is a more probable explanation
and warrants further investigation. 11-HSD-1 causes vis-
ceral obesity when overexpressed in transgenic mice (42),
but this effect is unlikely to be due to the upregulation of
agouti, as murine adipose tissue does not express agouti.
On the other hand, activity of 11-HSD-1 in human adipose
tissue is increased in visceral adipose tissue and has been
FIG. 5. Effects of agouti on adipocyte differentiation The preadipocytes from nontransgenic mice and BAP-agouti (BAP-a) transgenic were plated
and grown to confluence in DMEM/F12 with 15% FBS. At confluence, the cells were trypinized and split equally into 12-well plates After reaching
confluence the cells were induced to differentiate by changing the medium to DMEM containing 10% FBS, 0.5 mmol/l 3-isobutyl-1-methylxanthine,
1 mol/l dexamethasone, and 1.7 mol/l insulin. After 48 h, this medium was replaced with DMEM/F12 supplemented with 15% FBS, and cells were
maintained in this medium for 2 more days until fixed and stained with Oil Red-O. A: Adipocytes from nontransgenic mice. B: Adipocytes from
nontransgenic mice treated with 10 nmol/l agouti from the start of differentiation. C: Adipocytes from BAP-agouti mice. D: After photography the
Oil Red-O was extracted from the adipocytes with isopropanol and quantitated via spectrophotometry. Data are presented as means  SE and
are from two independent experiments with four wells per treatment. E: In a separate experiment RNA was isolated from preadipocytes at
confluency and after initiation of differentiation. RT-PCR was used to detect mRNA for PPAR and aP2 as markers of differentiation. OD, optical
density.
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proposed as a cause of central adiposity (43). Our data
suggest that agouti might play a role in central obesity as
a downstream target of glucocorticoids. Cortisol might be
produced locally via 11-HSD-1 or the result of an over-
active hypothalamic-pituitary-adrenal axis (44,45). Either
way, increased exposure of adipose tissue to cortisol
might serves as a stimulus for adipose tissue proliferation
and differentiation, and these data suggest that the auto-
crine/paracrine production of agouti is a putative mediator
of this effect.
When combined with previous studies in transgenic
mice overexpressing agouti, the functional implications of
increased agouti protein in adipose tissue are clear: agouti
blocks the antiproliferative effects of MSH and promotes
preadipocyte differentiation (probably through the upregu-
lation of PPAR). Thus, increased agouti is potentially
important as a paracrine factor in the regulation of adi-
posity, either during development or later in life. Given
that type 2 diabetes may be influenced by impaired adipo-
genesis and “spillover” of lipid into skeletal muscle and
liver (46), the upregulation of agouti mRNA in type 2
diabetes might be an attempt to proliferate and differenti-
ate new adipocytes in order to store excess lipid in
adipose tissue.
In conclusion, mRNA levels were significantly elevated
in subjects with type 2 diabetes. The regulation of agouti in
cultured human adipocytes revealed that insulin did not
regulate agouti mRNA, whereas dexamethasone treatment
potently increased the levels of agouti mRNA. This finding,
as recapitulated in vivo in humans, where increased ex-
pression of the cortisol-activating enzyme 11-HSD-1 was
upregulated in concert with agouti in type 2 diabetes.
Experiments with cultured human preadipocytes and with
cells obtained from transgenic mice that overexpress
agouti demonstrated that MCR signaling in adipose tissue
regulates both preadipoycte proliferation and differentia-
tion. Taken together, these results reveal that agouti can
regulate adipogenesis at several levels and suggest that
there are functional consequences of elevated agouti lev-
els in human adipose tissue. The influence of MCR signal-
ing on adipogenesis combined with the well-established
role of MCR signaling in the hypothalamus suggest that
adipogenesis is coordinately regulated with food intake
and energy expenditure.
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